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I am aware that I would not have had this oppor-
tunity to serve as your President this past year were it
not for the help of many others, and I wanted to rec-
ognize several individuals speciﬁcally. My surgical
residency years in Chicago enabled me to work closely
with David Skinner at the University of Chicago and
Steven Economou at Rush University (Fig. 1). Dr.
Skinnerwasamasterofclarityinthought,articulation,
and purposeful accomplishment. Dr. Economou was
the ﬁrst to show me the cognitive and technical aspects
of our specialty. A practitioner of multidisciplinary
oncology care long before the concept came into vo-
gue, Dr. Economou was proof positive that cancer
could be thought through and beaten back by knowl-
edge coupled to an ‘‘eloquent scalpel’’. Dr. Economou
was the ﬁrst to stimulate, and then encourage, my
aspirations to become a surgical oncologist, and for
this I will always be grateful.
During my fellowship at M.D. Anderson, I was
very fortunate to train under Dr. Richard Martin
(Fig. 2), one of the unsung heroes of American sur-
gery. Of all the many surgeons with whom I have ever
worked, Dr. Martin was unique in possessing
unsurpassed technical surgical brilliance coupled to
total—and at times even self-effacing—personal
humility. Dr. Martins unﬂagging devotion to the
cancer patient is why he was universally revered by
colleagues and trainees alike. Dr. Martin kindled my
interest in soft tissue sarcoma, and supported my
aspirations as a clinician–investigator during my fel-
lowship and initial faculty years. Dr. Martin was
succeeded as Chairman by Dr. Balch (Fig. 3). Charles
has had an enduring impact on my commitment to
academic surgical oncology—as is also the case for so
many of us here today. His energy, positive attitude,
and personal resilience are remarkable; I am lucky to
have him as my friend.
I am particularly grateful to the faculty of the
Department of Surgical Oncology at M.D. Anderson
(Fig. 4). Their loyalty to our patients, our trainees,
our academic pursuits, and to our department is
unﬂagging—my thanks to all of you for this. I have
been privileged to participate in training more than
150 fellows during my time at M.D. Anderson (Ta-
ble 1). We are proud of the accomplishments of this
amazing group, and are conﬁdent that they will move
this great enterprise along much farther than the
point we have reached today. My family of origin has
also had a profound impact. Growing up as the sec-
ond of ﬁve children taught me much about negotia-
tion and compromise. My father, the ﬁrst MD/PhD
that I ever met, was a most important mentor for
lessons about how to live purposefully, how to aspire,
and how to survive in the academic environment. My
greatest treasure is my own family, and between
raising our ﬁve children, faculty life at M.D. Ander-
son, and our shared sarcoma research program, my
wife Dina and I keep pretty busy.
It was diﬃcult to decide what to talk about today,
acutely aware that I am speaking to my colleagues,
trainees—current and former—and my friends: all of
you hope to come away from our conversation with
something of importance and meaning. I decided not
to speak of insights gained from my various roles as a
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661soft-tissue sarcoma surgeon, a department chairman,
a laboratory investigator, or a mentor and educator,
although I am very fortunate to have experienced all
of these. Instead, today I am speaking as your Pres-
ident, and I began thinking about this opportunity
and its responsibilities at about this time last year. To
be honest, at that point I was thinking more about
the opportunity to be creative than about the weight
of the responsibility. After the Society of Surgical
Oncology (SSO) meeting last year, when I returned to
Houston, I opened up a ﬁle labeled ‘‘SSO Address’’
and threw in interesting articles, as well as my own
occasional insomnia-fueled scribbles of half-baked
ideas, knowing that I had the summer months to
work on this project, which led to postponement until
after the American College of Surgeons meeting last
October, and then came the end-of-the-year holiday
season, and then…well, then there really was not
much more time left, and reading through the con-
tents of my SSO talk ﬁle did not lead to ﬂashes of
insight that might be molded into a coherent whole.
So I looked back on this year, serving as your Pres-
ident, and reﬂected that it has been a time of explo-
ration against the backdrop of this remarkable
professional honor, quite likely the highest that I will
ever receive. I realized that sharing my internal dia-
logue about how we might make a diﬀerence for our
Society and our specialty, and what we could do on
behalf of this good cause—I came to understand that
this should be the ‘‘stuﬀ’’ of my SSO presidential
address. So I have decided to use this opportunity to
oﬀer to you a report, an interim report to be sure, of
this year-long personal and professional journey. I
want to use these moments to focus your attention on
four concerns that—if handled eﬀectively—contain
the possibility for genuine growth of our Society, but
if ignored could have serious negative repercussions.
Together, we can consider some ﬁrst steps that might
be taken; for, as has wisely been advised, ‘‘control
your own destiny, unless you would rather have
someone else do it for you’’.
One such concern, moving rapidly to the front
burner, is the looming crisis in general surgical
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FIG. 1. David Skinner, University of Chicago. Steven Economou,
Rush University.
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realize that we need a strategy to cope with the threat.
This threat is real, if only because most of our
members are certiﬁed by the American Board of
Surgery (ABS), and all of the SSO-accredited surgical
oncology fellowship training programs require that
candidates be ABS eligible or certiﬁed. The overall
number of general surgeons in the US has stagnated
for more than 30 years (Fig. 5). Why has this hap-
pened? The answer is multifactorial. Nonetheless, we
need to scrutinize this problem so that we can tease
out and change those parts where we might have an
impact. One underlying factor is that US population
growth has simply outstripped our ability to train
surgeons, and this problem will only get worse as the
baby boomers move into the cancer-incidence age-
brackets over the next several years. Cancer will re-
place cardiovascular disease as the number one killer
of Americans sometime over the next several years,
and there will be more than twice as many people
aged 65 or older in the US 10 years from now—this is
our demographic reality. Medical workforce short-
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FIG. 4. Department of Surgical Oncology:
2007.
TABLE 1. Surgical Oncology Fellows: 1984–2008
Abdalla, Eddie Broadwater, John Fleming, Jason Laronga, Christine Pederson, Lee Spitz, Francis
Ahearne, Paul Byrd, David Fleming, Richard Leach, Steven Peoples, George Staley, Charles
Ahmad, Syed Camp, Ernest Fournier, Keith Lee, Jeffrey Pezzi, Christopher Stotter, Anne
Albo, Daniel Carlson, Grant Frederick, Wayne Lenert, Jeffrey Porter, Geoffrey Sussman, Jeffrey
Aloia, Thomas Carragher, Angela Fuhrman, George Ley, Phillip Portera, Charles Swanson, Richard
Al-Refaie, Waddah Choi, Eugene Gannon, Christopher Lim, Sherry Raut, Chandrajit Tada, Hiroomi
Amos, Keith Chun, Yun Shin Gershenwald, Jeffrey Lowy, Andrew Rawlings, Maurice Talamonti, Mark
Anaya, Daniel Cormier, Janice Gonzalez, Ricardo Lugo, Raul Reilly, James Tanabe, Kenneth
Andtbacka, Robert Corpron, Cynthia Graham, Roger Mansﬁeld, Paul Rippon, Mary Termuhlen, Paula
Archer, Stephen Couture, Jean Grau, Ana McBath, Mark Rodgers, Steven Thompson, William
Badgwell, Brian Curley, Steven Gray, Keith McCready, David Roseman, Barry Tseng, Jennifer
Barnes, George Cusack, James Grubbs, Elizabeth McMasters, Kelly Ross, Merrick Tuttle, Todd
Barnett, Carlton Dackiw, Alan Gutman, Haim Meric, Funda Rousseau, Dennis Tyler, Douglas
Barrera, Emilo Daneker, George Hardy, Mark Meterissian, Sarkis Royal, Richard Wang, Thomas
Bauer, Todd Daniel, James Heaton, Keith Midis, Gergory Ryan, Bernandette Watkins, Kevin
Bedrosian, Isabelle Davidson, Bradley Henderson, Michael Miller, Alexander Scaife, Courtney Wayne, Jeffrey
Beech, Derrick Delman, Keith Hoagland, Janet Mittendorf, Elizabeth Scoggins, Charles Whitworth, Pat
Beenken, Samuel Demers, Marc Hunt, Kelly Mortenson, Melinda Shenk, Robert Winchester, David
Bell, John Edwards, Michael Hurd, Thelma Mullen, John Shumate, Charles Wood, William
Berger, David Ehlers, Richard Hwang, Rosario Newman, Lisa Skibber, John Wray, Curtis
Berman, Russell Ehrenfried, John Izzo, Francesco Ng, Eng-Hen Sloan, David Yahanda, Alan
Bilimoria, Malcolm Ellis, Lee Kahky, Michael Nieweg, Omgo Smith, David Yeatman, Timothy
Blazer, Dan Esgro, Joseph Katz, Mathew Parikh, Alexander Smith, Jeffrey Yen, Tina
Bold, Richard Esnaola, Nestor Kesmodel, Susan Pawlik, Timothy Smith, Mark Zager, Jonathan
Bouvet, Michael Evans, Douglas Kokotsakis, John Pearlstone, David Solorzano, Carmen
Breslin, Tara Feig, Barry Lambert, Laura Pearson, Adrian Souba, Wiley
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appear to be amongst the worst in surgery, where the
per capita number of general surgeons is at a 50-year
low. Not only is the rate of general surgical growth
slower than that of the general population, but it is
also markedly less in absolute terms than that of
nonsurgical medical specialties. Add to this picture
the unresolved medical liability crisis, the accelerating
time demands of medical documentation, and the
erosion in all types of payer compensation—is any-
one surprised that the average retirement age for US
general surgeons now hovers in the mid-50s?
On the macro level, the Federal government has
supported the opening of four new medical schools
by 2009, the ﬁrst such expansion since 1982. But will
this take care of the problem? Obviously not, and I
suggest we can help, on a daily basis, by looking at
how we work as role models and mentors for our
medical students and surgical trainees. Our trainees
are confronted by many new challenges that most of
us never faced: massive educational debts, literally
compounded by the length of time needed to become
‘‘fully trained’’ —and how long will that take in this
‘‘Brave New World’’ of the 80-hour work-week?
These young people are appropriately questioning
how much additional time beyond residency will be
needed to become a truly autonomous surgeon, and
our positive mentoring (or lack thereof) will go a long
way towards resolving (or exacerbating) these con-
cerns.
Most medical students decide on their specialty
during their third year clinical clerkships. The shorter
length of surgical rotations decreases student expo-
sure to surgical residents and attendings, which fur-
ther erodes our contact time as mentoring role
models. As reported in 2004 by the American Surgi-
cal Association Blue Ribbon Committee,
1 students
who received effective mentoring were much more
likely to opt for surgical careers and less likely to be
as concerned about time-commitment issues, call
schedules, debt loads etc. It is particularly gratifying
that the dip in general surgery residency applicant
numbers seen earlier this decade has now been cor-
rected, and almost all training slots are currently
being ﬁlled. So here is idea number one: we must
continue in our strong efforts to be the best possible
role models for our students and our residents—and
those of us in positions of authority should reinforce
a culture in our departments where the quality of
these mentoring efforts are recognized and rewarded
in our evaluation and promotion systems.
There are other actions that we can take to help
strengthen perceptions about surgical training, the
entrypointintoasurgicaloncologycareer.Hereisidea
number two: what about targeted outreach programs
that would enable medical students to attend the SSO
annual meeting, perhaps by funding a substantial
number of student travel scholarships? These students
are our germline DNA, and they are worthy of our
active cultivation. We also need to better understand
the optimal size of the surgical oncology manpower
pool. Consider the 2006 fellowship match results (Ta-
ble 2). Nationally, is there perhaps too much capacity
for CVT training and not enough for surgical oncol-
FIG. 5. Source: American Medical Associa-
tion (AMA): physician characteristics and di-
stribution in the US, 2006 edition.
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accredited training programs came online in time for
the fellowship match this past year, with others in the
planning stage. Nonetheless, we had to turn away
many highly qualiﬁed individuals. Idea number three:
we can determine future surgical oncology manpower
needs utilizing currently available data, leading to a
rational basis for continued increases in SSO-accred-
ited surgical oncology fellowship training positions.
Those of us in academic leadership roles, armed with
this data, could approach our local powers-that-be to
help garner the resources needed for increased surgical
oncology fellowship positions.
A second emerging issue that is critical to our
specialty, where the SSO has a major potential role to
play, is the possibility of establishing board certiﬁ-
cation in surgical oncology. The past half-century has
seen the unprecedented evolution of surgical special-
ties into their current status as discrete disciplines,
with specialized knowledge, techniques, anatomic
challenges, and diseases of focus. This is especially
true in surgical oncology, which has attracted most of
us due to its strong allure as a combination of the
technical and the cognitive. For the past three dec-
ades the political waters have been less favorable for
surgical oncology to be recognized as a distinct sur-
gical specialty. However, there is an emerging
understanding that the surgical oncologist has spe-
cialized knowledge that is not acquired in general
surgical training: knowledge of the natural history of
malignant disease, knowledge of multidisciplinary
care for the cancer patient, and certainly, knowledge
of how to perform some very unusual and technically
demanding oncological operative procedures. These
factors, coupled with an awareness of the rapidly
increasing solid-tumor patient volume, have led to an
active interest in creating a board certiﬁcation
mechanism for surgical oncology. Board certiﬁcation
in surgical oncology would impact on almost all of
the issues we are discussing today. Certainly our
identity as a surgical specialty would be reinforced in
the eyes of trainees, Congress, other surgical societies,
and the medical centers where we work. Predictably,
the availability of board certiﬁcation will increase the
enthusiasm of young surgeons to pursue a career in
this ﬁeld. Further expansion, standardization, and
upgrades of our already strong fellowship training
programs can be anticipated to follow in short order.
Board certiﬁcation would also strengthen the position
and impact of surgical oncologists practicing in the
community, and might also aid in the development of
comparable certiﬁcation mechanisms in other coun-
tries from which we increasingly hope to draw SSO
membership. Our SSO membership survey, con-
ducted earlier this year, clearly demonstrates that
more than two-thirds of our members want board
certiﬁcation in surgical oncology, and that they ex-
pect the SSO to help facilitate this possibility.
In our era of pay for performance, deﬁnable out-
comes, and transparent quality-assurance programs,
surgical oncology board certiﬁcation would enable us
to be more of a force to positively aﬀect these con-
cerns. For example, the American College of Sur-
geons National Surgical Quality Improvement
Program (NSQIP), discussed in the Clinical Aﬀairs
Committee Forum yesterday, is the ‘‘ﬁrst nationally
validated, risk-adjusted, outcomes-based program to
measure and improve the quality of surgical care.
Medical centers and their surgical staﬀ are able to use
the data to make informed decisions regarding their
continuous quality improvement eﬀorts’’.
2 NSQIP
includes 136 variables, and allows comparison of
hospitals, specialties, procedures, and even surgeon-
speciﬁc outcomes. Will outcomes data like this be
used only by medical centers and their surgical staff?
Ultimately, I think not. And so I draw your attention
to the new NSQIP multi-specialty high-volume online
calculator issued on February 7, 2007 (Fig. 6). Listed
are the ten surgical specialties included in the NSQIP
model; this list does not include surgical oncology.
Would we perhaps have a more visible presence in the
future if we were a board-certiﬁed specialty? Hope-
fully the Outcomes Task Force, newly created this
past year, will help us in this critical endeavor. The
Disparities Task Force, launched this past year, will
also have a major role to play in this and many other
signiﬁcant issues about the adverse impact of dis-
parities on cancer care and outcomes.
How board certiﬁcation in surgical oncology will
be implemented is the next order of business. The
Directors of the American Board of Surgery, which
includes several members of the SSO Executive
Council, has unequivocally indicated that the time is
ripe to begin this process in earnest. Several of us
represent the SSO as members of the Surgical
Oncology Advisory Council of the American Board
of Surgery, and we are developing a multi-step action
plan that will require much concerted eﬀort by all of
TABLE 2. 2006 Specialty Fellowship Match Results
Surgical Oncology CVT
Number of positions 46 140
Number of applicants 69 90
Number of positions unﬁlled 0 50 (36%)
Number of applicants unmatched 23 (33%)0
Source: SSO and NRMP.
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years at a minimum, and will require our fellowships
to be accredited by the American Council of Grad-
uate Medical Education (ACGME). Once we have
ACGME accreditation, the American Board of Sur-
gery will be able to work with the SSO to develop
board certiﬁcation in surgical oncology. This past
year we created a Board Certiﬁcation Task Force, led
by James Goodnight, to advise the SSO Executive
Council while providing a direct communication link
for you, the members of our Society. Please stay
tuned!
A third major issue worthy of consideration is how
to help the SSO become more inclusive, by vigorously
embracing both US community surgical oncologists
as well as surgical oncologists practicing abroad. To
be honest, if we continue to view the SSO primarily as
the domain of US academic surgical oncologists, we
may well be undercutting our ultimate potential for
inﬂuence. Expanded strength and vitality will come
from inclusion and diversity and not by narrowness
and exclusivity. You may disagree with me, but I
believe that the hour is later than we think, and we
should move aggressively now. To begin this eﬀort,
this year we created two new SSO Committees: the
Community Surgical Oncology Committee and the
International Surgical Oncology Committee. To
make certain that these new committees can be heard
loud and clear, their chairmen have been invited to
become members of the SSO Executive Council. Why
do we need to do this? Simply stated, if we want to
aﬀect the quality of surgical oncology care we must
F February 7, 2007 
 
NEW! Multi-Specialty Model High Volume Online Calculator 
 
The subspecialties that will be included in the multi-specialty model are: 
1. General 
2. Vascular 
3. Urology 
4. Neurosurgery 
5. Orthopedics 
6. Otolaryngology 
7. Plastic 
8. Thoracic 
9. Gynocology 
10.Cardiac Surgery  FIG. 6. Multi-specialty model high-volume
online calculator.
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resections in the US are performed in the community.
If surgical oncology is to provide leadership in con-
temporary multidisciplinary cancer care, we must
embrace those surgeons who are providing the bulk
of cancer surgery. This is important, not only to as-
sure the public that they are receiving the highest
quality of oncology care, but also for more speciﬁc
tasks, for example, patient accrual to clinical trials
such as those conducted by the American College of
Surgeons Oncology Group (ACOS/OG). Over the
past 12 months, the SSO has forged a strategic
partnership with ACOS/OG to help reach mandated
patient accrual targets needed to successfully renew
National Cancer Institute (NCI) funding. We all have
a critical stake in the success of ACOS/OG; were it to
fail, it is very unlikely that another National Insti-
tutes of Health (NIH)-funded surgical oncology
‘‘trialist’’ group will ever emerge.
There are other reasons why this is important to do.
In many community hospitals, the link between sur-
gicalvolumeandoutcomesfeedsaviciouscycle,fueled
by the tort reform crisis, where the surgical staﬀ is
under pressure to refer the more diﬃcult cases to the
cancer centers, leading to the erosion of surgical
oncology skills in the community, which in turn will
lead to even more referrals to the centers.And those of
usinthecancercentersknowthat,withourtypical85–
90% inpatient occupancy rates, we may not be able to
easily absorb large additional referral volumes. Board
certification could help stabilize this trend. It could
also better position community surgical oncologists
vis-a ` -vis other oncology specialists as well as hospital
administrations that only variably respond to our
professional needs. As you can see, these problems
intertwine, but as the old Chinese proverb goes:
‘‘Within a problem lies the seeds of a solution’’. For
sure, this is not a time for complacency.
Why should we be more aggressive in engaging the
international surgical oncology community? In this
era of pervasive globalization, with near-instanta-
neous information transfer via the Internet, we are
now truly tied together as a global village, as Mar-
shall McLuhan predicted 30 years ago. If we do not
embrace this reality, we will be missing a remarkable
opportunity to help ﬁll the organizational leadership
gap in international surgical oncology. Already we
have a long tradition of international membership,
with members from 41 countries at the last count.
Compare this to the American Society of Clinical
Oncology (ASCO), for example, which over the past
25 years has increased in size from 3000 to 25,000
members from 110 countries, and our own potential
for international surgical oncology growth and lead-
ership becomes apparent. But to come back to the
original question: why should we do this? And I an-
swer as follows: we in the US do not have a
monopoly on surgical innovation, and we can either
read about new approaches being developed in other
countries or facilitate the SSO as the disseminator of
these advances—it is our choice at this point, al-
though the window of opportunity will not remain
open forever. We have many lessons to learn from
our overseas colleagues. Accruing patients to clinical
trials, we must be candid, has generally been done
much better abroad than here. We could learn from
the European Organisation for Research and Treat-
ment of Cancer (EORTC), for example, rather than
continue to excuse ourselves from this responsibility.
The SSO could become the major international for-
um where the important discussions and debates take
place. As an example, consider our relatively modest
impact, as an organization, on the international tri-
als-based debate about the extent of nodal dissection
for gastric cancer that has occurred over the past 20
years. Without elaborating further, I think that you
get the gist of my point. Another important area
where an enhanced international presence might be
very useful is in international oncology education.
This endeavor would be natural for a more interna-
tionally ﬂavored SSO. In the past, eﬀorts led by Hugo
Villar, Charles Balch, and others, initially under the
aegis of the American College of Surgeons Commis-
sion on Cancer, and more recently via the Interna-
tional Education Committee of ASCO, were very well
received. Once again this important international
oncology education program is without a sponsoring
organizational home, and the SSO could help as part
of an expanded international presence. Working with
a broader membership base, a mix of US and inter-
national surgical oncologists could serve as educa-
tional teams that could reach many underserved
locations throughout the world, where such eﬀorts
are badly needed and would be deeply appreciated.
All of these many activities could be accomplished
by an enlarged SSO membership of more diverse
phenotype. I am certain that this can happen without
negatively aﬀecting—but instead positively extend-
ing—our mission and vision as the Society of Surgical
Oncology. In addition, a broadened membership base
will also directly beneﬁt the SSO, not only due to
enhanced membership dues revenue, but also because
of the power inherent in a diverse organization with
the throw-weight of several thousand more members,
positioned to speak on behalf of surgical oncologists
everywhere.
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creation of the Community and the International
Surgical Oncology Committees, with guaranteed
representation on the SSO Executive Council. A
necessary next step will be to revise our SSO mem-
bership, which currently has several diﬀerent cate-
gories, and replace it with one designation, called
‘‘member’’, with identical privileges of membership
for all members—period!
I would like to discuss one ﬁnal opportunity for the
SSO. How can we be best positioned to fully partic-
ipate in the molecular-based revolution in oncology?
This is rapidly leading to clinical deployment of
nontoxic, personalized oncology therapeutics based
on high-throughput assessment of patient and tumor
biomarkers. If we do not vigorously participate in
this as committed stakeholders, a remarkable
opportunity will pass us by, and ultimately our role in
multidisciplinary cancer care can be predicted to
shrink as well. It is tremendously exciting to work in a
ﬁeld where the knowledge base is expanding expo-
nentially, and where there are major opportunities to
partner with other oncology specialists, using our
complementary expertise, on behalf of our shared
patients. At the same time, it is important to keep in
mind that we are usually the ﬁrst oncologist to see a
patient, and that we will have ﬁrst access to the tumor
tissues so vital to contemporary molecularly oriented
oncology research. These are very powerful ‘‘ﬁrsts’’!
It is especially gratifying that so many young surgical
oncologists want to acquire the investigative skills
needed for preclinical translational research and
clinical trials testing. Almost certainly, this can lead
to an expanded cadre of surgical oncologists who are
able to develop and administer personalized molec-
ularly targeted onco-therapeutics. To facilitate this
possibility, this past year the SSO leadership has be-
gun to engage ‘‘Big Pharma’’ in a concerted eﬀort to
create clinician-investigator awards, the so-called
CIA program. With a rapidly growing inventory of
non-toxic molecules and biological therapies, many
administered orally, ‘‘Big Pharma’’ recognizes that
surgical involvement will also be essential in design-
ing new trials that have ‘‘surrogate biological end-
points’’. Upon maturity, the CIA program will
annually fund ten or more additional young surgical
oncologists. I am delighted to be able to report that
three CIA awards are being given this year, hopefully
with more in the pipeline for next year. Many thanks
to the SSO Fellowship and Research Grant Com-
mittee, led by James Economou, and to the many
other members of the SSO, especially Charles Balch,
Kelly McMasters, and Nick Petrelli, who participated
in fund raising trips and dialogue with ‘‘Big Pharma’’.
Without their eﬀorts this new program would not
have got oﬀ the ground.
So we come to the end of my story about these four
magniﬁcent opportunities for our Society. But this is
really the just the take-oﬀ point from which we must
go forward. How to coalesce these initial eﬀorts into
a course of action? As Yogi Berra, the famous base-
ball player of the New York Yankees, once said:
‘‘You got to be careful if you dont know where
youre going, because you might not get there’’. With
this admonition in mind, we began with an SSO
membership survey last spring to learn more about
your feelings on these issues. This segued into an SSO
Executive Council retreat last summer, out of which
came a revised SSO mission and vision statement and
new SSO strategic plan, an eﬀort last undertaken in
1991 (Table 3). This strategic plan can be a blueprint
for our future actions, and is worth a careful personal
study. See if it speaks to your needs as a member of
the SSO. Contained within it are many strategic
opportunities that will enable each of us to become
even more fully involved. In my waning moments as
TABLE 3. SSO Strategic Plan 2007–2010. Approved 10-9-06
Goal 1 – Multi-specialty member needs
SSO will provide for professional needs of its multi-specialty membership, both domestic and international.
Goal 2 – Education and training
SSO will provide continuing education, training and workshops designed to meet the needs of its diverse membership.
Goal 3 – Clinical and translational research
SSO will promote high-quality clinical and translational research in surgical oncology, with a focus on clinical trials and outcomes
research.
Goal 4 – Career development
SSO will help new surgical oncology specialists and trainees establish productive careers and practices, both in academic and
community settings.
Goal 5 – Quality of cancer care and practice management
SSO will strive to enhance the quality of life and survival of the surgical patient with cancer, and improve the practice environment in
which high-quality surgical oncology care is delivered.
Goal 6 – Governance and operations
SSO will optimize its organizational vitality, its operational excellence, and its technological capacity.
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privilege of leadership that you have bestowed on me
this past year, a deﬁning moment in my surgical
oncology career. I will leave you with the words of
Alexander Graham Bell: ‘‘Great discoveries and
improvements invariably involve the cooperation of
many minds’’. Working together I am certain that we
can make things better. Its been a great year. Thank
you for your trust and your attention.
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